<DOC>
	<DOC>NCT01181609</DOC>
	<brief_summary>This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum. The anticipated time of study treatment is until disease progression.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with metastatic colon or rectal cancer, progressing or relapsing after firstline treatment; Women of childbearing potential must use adequate contraception up to at least 6 months after the last dose of bevacizumab. Patients with metastatic colon or rectal cancer scheduled for a firstline systemic treatment; Untreated brain metastases, spinal cord compression or primary brain tumours; Pregnant or lactating women; Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study start; Treatment with any investigational drug, or participation in another investigational study, within 30 days prior to enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>